About This Project
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Recent Lab Notes From This Project
Browse Other Projects on Experiment
An Adaptive Radiation Under Our Feet? Examining Diversification Patterns in New World Leaf-litter Geckos
Adaptive radiations occur when an evolutionary lineage diversifies and adapts to use a previously unoccupied...